CGI Laboratories becomes a Center of Excellence for the management of Chronic Lymphocytic Leukemia (CLL) by servicing world-class and proprietary assays. CLL Complete integrates the latest prognostic molecular markers to risk-stratify individual patients for disease progression, response to treatment, and overall prognosis.
CLL Complete -Test Offering
MatBA™-CLL Array-CGH Assay - CLIA and New York State licensed - The Mature B-Cell neoplasm array for CLL (MatBA™-CLL) identifies gain/loss of genomic material frequently observed in CLL. Loss of 17p, 11q, and 8p, and gain of 2p, 3q, and 8q, are associated with poorer overall outcome while loss of 13q with a favorable outcome. Gain of chromosome 12 is neutral.
IGHV Mutation Analysis - Found in approximately 50% of CLL patients, IGHV gene hypermutation serves as an independent prognostic marker. Patients with the hypermutated IGHV exhibit a better overall survival than those with unmutated IGHV. Utilization of IGHV3-21 is associated with an unfavorable outcome.
TP53 Mutation Analysis - Presence of a TP53 mutation is associated with short survival and resistance to chemotherapy.
NOTCH1 Mutation Analysis - Mutational NOTCH1 activation at CLL diagnosis is emerging as an independent predictor of poor survival
ZAP-70 - Independent prognostic marker of CLL used as a surrogate marker for IGHV mutation analysis. High level of ZAP-70 protein correlates with aggressive disease.
CD38 - Independent prognostic marker. High expression of CD38 is associated with an unfavorable clinical course.
FISH Panel – Reports with high sensitivity key prognostic markers including loss of 17p (TP53), 11q (ATM), 13q, and 6q, and gain of 12. Translocation of 11 and 14 is also evaluated to rule out Mantle Cell Lymphoma.
Karyotyping - Genome-wide detection of aberrations at low resolution with diagnostic and prognostic significance for CLL.
To get more information about our CLL Complete service, please contact us at 201-528-9204 or at contact@cancergenetics.com.
